Odyssey Therapeutics, Inc.
USD · NASDAQ:ODTX
Issue Size
$225.08M
Price Range
$16.00 - $18.00
Shares
47.17M o/s · 13.24M offered
Listing Price
$20.00
Listing date
May 08, 2026
Sector
Healthcare
About
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Odyssey Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:ODTX
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Risk Metrics
Volatility versus the market
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | $17.95 | $18.02 | $16.86 | $17.01 | $17.01 | -0.94 | 165,300 |
| 2026-05-28 | $17.35 | $18.31 | $16.73 | $17.92 | $17.92 | +0.57 | 309,200 |
| 2026-05-27 | $17.97 | $18.30 | $17.04 | $17.19 | $17.19 | -0.78 | 405,100 |
| 2026-05-26 | $17.24 | $18.30 | $16.98 | $17.56 | $17.56 | +0.32 | 400,100 |
| 2026-05-22 | $17.56 | $18.43 | $16.50 | $17.50 | $17.50 | -0.06 | 323,600 |
| 2026-05-21 | $17.00 | $18.24 | $16.75 | $17.74 | $17.74 | +0.74 | 408,100 |
| 2026-05-20 | $16.93 | $17.50 | $16.78 | $16.97 | $16.97 | +0.04 | 389,000 |
| 2026-05-19 | $17.39 | $17.65 | $16.75 | $16.94 | $16.94 | -0.45 | 376,500 |
| 2026-05-18 | $17.55 | $17.71 | $17.00 | $17.39 | $17.39 | -0.16 | 371,800 |
| 2026-05-15 | $17.15 | $17.86 | $17.00 | $17.62 | $17.62 | +0.47 | 405,100 |
| 2026-05-14 | $17.92 | $17.94 | $17.08 | $17.32 | $17.32 | -0.60 | 356,700 |
| 2026-05-13 | $18.06 | $18.06 | $17.40 | $17.94 | $17.94 | -0.12 | 316,300 |
| 2026-05-12 | $17.61 | $18.06 | $17.27 | $17.90 | $17.90 | +0.29 | 171,200 |
| 2026-05-11 | $16.56 | $17.72 | $16.41 | $17.45 | $17.45 | +0.89 | 427,000 |
| 2026-05-08 | $20.00 | $20.30 | $15.35 | $16.42 | $16.42 | -3.58 | 3,170,900 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | May 18, 2026 | Filing |
| SCHEDULE 13D | May 18, 2026 | Filing |
| SCHEDULE 13D | May 18, 2026 | Filing |
| SCHEDULE 13D | May 15, 2026 | Filing |
| SCHEDULE 13D | May 15, 2026 | Filing |
| 8-K | May 11, 2026 | Current Report |
| S-8 | May 11, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | May 8, 2026 | Prospectus |
| EFFECT | May 7, 2026 | Notice of Effectiveness |
| S-1MEF | May 7, 2026 | Registration adding securities to prior Form S-1 registration |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Gary D. Glick, Ph.D.
President, Chief Executive Officer and Director
Julie Clauss
Chief Operating Officer
Jason Haas
Chief Financial Officer
William Roush, Ph.D.
Executive Vice President, Head of Small Molecule Research
Kira M. Schwartz
Executive Vice President, General Counsel and Secretary
Stephen Soisson, Ph.D.
Executive Vice President, Protein Therapeutics and Structural Biology
Collin Todd
Senior Vice President, Strategy and Business Development
Jeffrey M. Leiden, M.D., Ph.D.
Chair and Director
Charles Baum, M.D., Ph.D.
Director
Jill Carroll
Director
